CONSIDER ENROLLING IN A HYPOTHALAMIC OBESITY CLINICAL RESEARCH STUDY
The SIGNAL Study is a clinical research study looking at an investigational once-daily tablet for people with hypothalamic obesity. The study aims to see if the investigational tablet is safe and effective in reducing body mass index (BMI) and excessive hunger in people with hypothalamic obesity.
You, or your child, may be able to take part if you/they:
- are 12 years of age or older
- have a BMI that is:
- 30 kg/m2 or over (if you are 18 years of age or older)
- in the 95th percentile or higher (for children 12–17 years of age)
- have been told by a doctor that you/they have a tumor, lesion, or injury affecting the hypothalamic region of the brain.
Additional criteria to take part apply.
People taking part will have up to 12 study center visits and 1 phone call over the course of this study. The first part of the study will last for 14 weeks. Those who wish to continue may be able to participate for an additional 38 weeks in an extension study. Participation in the study may last up to 1 year and 3 months (64 weeks).
Want to know more? Download a brochure or email patientadvocacy@rhythmtx.com
This study has been reviewed by an Institutional Review Board (IRB)/Ethics Committee (EC), which protects the rights, safety, and well-being of the participants.
